Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)

NCT ID: NCT04134169

Last Updated: 2022-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

28 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-02

Study Completion Date

2026-04-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Multi-center, Open, Long-term Follow-up Study to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid arthritis: 5-year Results From the K0202 Extension Study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rheumatoid arthritis

Not applicable(observational study)

Intervention Type OTHER

Not applicable(observational study)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Not applicable(observational study)

Not applicable(observational study)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject who enrolled K0202 Clinical Trial(parent study) and has been given more than one medication.
2. Subjects who understand and voluntarily sign an informed consent form

Exclusion Criteria

1\. Any other condition which the investigator judges would make patient unsuitable for study participation
Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kang Stem Biotech Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul national University Boramae medical center

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chae Eun Jeon

Role: CONTACT

+82-2-20367614

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sanghui Kim

Role: primary

+82-2-8703969

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K0202-E

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

An Open-label Study of GC012F in Rheumatoid Arthritis.
NCT07315503 NOT_YET_RECRUITING EARLY_PHASE1